Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient

18Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

A 48-year-old man, with end-stage renal disease (ESRD) on haemodialysis, presented to the emergency department with sulphonylurea-induced hypoglycaemia. His hypoglycaemia was persistent despite glucose infusion, so he was treated with octreotide. Octreotide administration reversed the hypoglycaemia but also resulted in severe hyperkalaemia. The patient was urgently dialysed, the octreotide was discontinued and his potassium normalized. We believe that the hyperkalaemia was caused by octreotide-induced insulin suppression and resultant impaired cellular potassium uptake. Although octreotide may be an effective therapy in refractory sulphonylurea-induced hypoglycaemia, it should be used with caution in patients on dialysis. © The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Cite

CITATION STYLE

APA

Adabala, M., Jhaveri, K. D., & Gitman, M. (2010). Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrology Dialysis Transplantation, 25(10), 3439–3442. https://doi.org/10.1093/ndt/gfq381

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free